proteomics.com.auCrawled Nov 15, 2026
Proteomics International offers biomarker discovery, verification, and analytical validation services through its Promarker technology platform—a powerful mass spectrometry-based approach for identifying protein biomarkers.
A company reports positive experiences with Proteomics International’s analytical services for biosimilars and biologics drug characterization.
Proteomics International’s product pipeline identifies protein biomarkers linked to clinical conditions by comparing biological samples.
PromarkerEso is a blood test detecting proteomic changes to rule out esophageal adenocarcinoma in patients with chronic reflux.
Senior consultant pathologist, and Professor of pathology, at Tufts University Medical School and President of Dr. Robert Odze Pathology LLC (Odzepathology.com)
Proteomics International provides company presentations on PIQ.
The Promarker tests aim to improve patients’ quality of life by addressing specific conditions.
The page explains the science behind the PromarkerD test and its research.
Quarterly Activities/Appendix 4C Cash Flow Report
Proteomics International licenses the PromarkerD test for diabetic kidney disease in Chile through Omics Global Solutions.
Proteomics International expands into Europe with Growth Medics to promote the PromarkerD test for diabetic kidney disease.
Proteomics International signs a deal with Eurobio Scientific for exclusive distribution of the PromarkerD test in France.
Proteomics International partners with Eurobio Scientific to distribute the PromarkerD test in France under a five-year agreement.
Proteomics International specializes in predictive diagnostics and bio-analytical services, focusing on proteomics for early disease detection.
Adjunct Clinical Professor, Curtin Medical School, Curtin University Consultant Gastroenterologist Royal Perth Hospital, Perth, Australia Honorary Professor, School of Medicine, University of Nottingham, UK
Dr. Andrew Frankel is a nephrologist specializing in kidney disease and diabetes management at Imperial College Healthcare NHS Trust.
Professor Thomas is a nephrologist and expert in diabetic kidney disease at Monash University and RAGE Biotech Ltd.
Professor Davis is a consultant physician and endocrinologist at Fremantle Hospital and The University of Western Australia, with over 40 years in diabetes research.
Dr. Andrew C. Chang is a thoracic surgeon specializing in esophageal and thoracic oncology at the University of Michigan.
Director, Esophageal Surgery Program, Associate Professor, Cardiothoracic Surgery Weill Cornell Medical College Associate Attending Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, NY
Corporate Governance Statement 2026 View document
To view Investor Presentations prior to 2020, please visit the ASX website here.
Commercialisation of protein-based precision diagnostics through transparent communications with shareholders and investors.
Proteomics International ensures scientific integrity, clinical reliability, and regulatory compliance across its research, diagnostics, and product development.
Proteomics International handles commercialization-related inquiries through a business development team.
Harry Perkins Institute of Medical Research Level 1, 6 Verdun Street Nedlands Perth WA 6009 Australia
The growth in the markets for protein-based therapeutics has led to a demand for analytical expertise often beyond “in-house” capacity.
Proteomics offers biomarker and drug development analytical testing in its ISO 17025 accredited laboratory.
Laboratories can request technical support for Proteomics products by providing region-specific details.
The company develops protein-based diagnostics, including Promarker tests, for early disease detection.
The Proteomics International Privacy Policy details how personal information is collected, used, and protected.
Proteomics International (ABN 78 096 013 455).
View the Terms of Use for MyTEST Australia, including healthcare provider requirements, diagnostic testing access, and website use.
The page outlines the terms of use for Promarker diagnostic pages in the United States.